NYSE - Nasdaq Real Time Price USD

Novartis AG (NVS)

Compare
115.21 +1.44 (+1.26%)
As of 10:46 AM EDT. Market Open.
Loading Chart for NVS
DELL
  • Previous Close 113.77
  • Open 115.14
  • Bid 115.10 x 1000
  • Ask 115.13 x 1100
  • Day's Range 114.97 - 115.40
  • 52 Week Range 92.19 - 120.92
  • Volume 199,779
  • Avg. Volume 1,161,317
  • Market Cap (intraday) 234.084B
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) 23.56
  • EPS (TTM) 4.89
  • Earnings Date Oct 29, 2024
  • Forward Dividend & Yield 3.78 (3.32%)
  • Ex-Dividend Date Mar 7, 2024
  • 1y Target Est 117.90

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

www.novartis.com

76,057

Full Time Employees

December 31

Fiscal Year Ends

Recent News: NVS

View More

Performance Overview: NVS

Trailing total returns as of 10/9/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NVS
18.46%
MSCI WORLD
16.72%

1-Year Return

NVS
23.13%
MSCI WORLD
0.00%

3-Year Return

NVS
56.99%
MSCI WORLD
0.00%

5-Year Return

NVS
64.27%
MSCI WORLD
74.14%

Compare To: NVS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NVS

View More

Valuation Measures

Annual
As of 10/8/2024
  • Market Cap

    230.04B

  • Enterprise Value

    250.59B

  • Trailing P/E

    23.27

  • Forward P/E

    14.01

  • PEG Ratio (5yr expected)

    1.73

  • Price/Sales (ttm)

    4.80

  • Price/Book (mrq)

    5.52

  • Enterprise Value/Revenue

    5.13

  • Enterprise Value/EBITDA

    13.20

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    33.11%

  • Return on Assets (ttm)

    8.86%

  • Return on Equity (ttm)

    21.50%

  • Revenue (ttm)

    48.86B

  • Net Income Avi to Common (ttm)

    10.08B

  • Diluted EPS (ttm)

    4.89

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.43B

  • Total Debt/Equity (mrq)

    69.18%

  • Levered Free Cash Flow (ttm)

    14.81B

Research Analysis: NVS

View More

Company Insights: NVS

Research Reports: NVS

View More

People Also Watch